# P2-B ADR Traceability Matrix

**Horizon:** 1 (Architecture Foundation Framework)  
**Phase:** P2-B (Provider Integration & Architecture Validation)  
**Document Type:** ADR Traceability Matrix  
**Date:** 2026-07-11  
**Authority:** Chief Architect

---

## Purpose

This matrix provides **bidirectional traceability** between:

- **ADRs** (Architecture Decision Records)
- **Evidence** (test results, logs, traces, metrics)
- **Success Criteria** (from SUCCESS-CRITERIA-PER-LEVEL.md)
- **Quality Attributes** (from QUALITY-ATTRIBUTE-SCENARIOS.md)

**Critical Principle:**

> **Every ADR MUST have evidence. Every evidence artifact MUST trace to ADR.**

---

## Matrix Structure

### Forward Traceability (ADR → Evidence)

```
ADR-XXXX
    ↓
Success Criteria (which criteria does this ADR support?)
    ↓
Quality Attribute (which quality attributes does this ADR address?)
    ↓
Evidence Artifacts (which evidence validates this ADR?)
```

### Backward Traceability (Evidence → ADR)

```
Evidence Artifact (EVD-XXX)
    ↓
Claims Validated (which architectural claims does this evidence support?)
    ↓
ADR Reference (which ADR does this evidence validate?)
    ↓
Success Criteria (which success criteria does this evidence satisfy?)
```

---

## P0 ADRs (Before Implementation)

### ADR-1001: Provider Abstraction Strategy

**Status:** NOT YET WRITTEN (P2-B not started)

**When Written, Trace to:**

**Success Criteria:**
- Provider Independence (SUCCESS-CRITERIA-PER-LEVEL.md, P2-B Level 1)
- Capability Parity (SUCCESS-CRITERIA-PER-LEVEL.md, P2-B Level 1)

**Quality Attributes:**
- QA-MAINT-001: Provider Addition (<2 days, zero consumer changes)
- QA-EXTEND-001: New Provider Integration (<2 days implementation)

**Evidence Required:**
- EVD-001-L3: Provider Swap Test
- EVD-002-L3: Provider Abstraction Test Suite
- EVD-003-L3: Zero Consumer Changes Validation

**Validation Questions:**

1. Does provider abstraction support ≥3 implementations?
2. Does provider replacement require zero consumer changes?
3. Does context lifecycle remain identical across all providers?

**Exit Criteria:**

- [ ] ADR-1001 written and accepted
- [ ] All evidence artifacts created
- [ ] All validation questions answered (YES)

---

### ADR-1006: Provider Credential Management

**Status:** NOT YET WRITTEN (P2-B not started)

**When Written, Trace to:**

**Success Criteria:**
- Security (SUCCESS-CRITERIA-PER-LEVEL.md, Cross-Cutting)

**Quality Attributes:**
- QA-SEC-001: No Secrets in Code/Logs
- QA-SEC-002: Credential Rotation (<1 hour downtime)

**Evidence Required:**
- EVD-010-L3: Credential Storage Test
- EVD-011-L3: Credential Rotation Test
- EVD-012-L2: Code Review (no hardcoded secrets)

**Validation Questions:**

1. Are provider credentials stored securely?
2. Can credentials be rotated without downtime?
3. Are credentials never logged or exposed?

**Exit Criteria:**

- [ ] ADR-1006 written and accepted
- [ ] All evidence artifacts created
- [ ] All validation questions answered (YES)

---

### ADR-1050: ACOS Observability Strategy

**Status:** NOT YET WRITTEN (P2-B not started)

**When Written, Trace to:**

**Success Criteria:**
- Observability (SUCCESS-CRITERIA-PER-LEVEL.md, P2-B Level 1)

**Quality Attributes:**
- QA-AVAIL-002: Incident Detection (<5 minutes)
- QA-PERFORM-002: Request Traceability (100% requests traceable)

**Evidence Required:**
- EVD-020-L3: Trace Completeness Test (100% requests traceable)
- EVD-021-L3: Observability Explains WHY (reasoning traces)
- EVD-022-L2: Trace Example (end-to-end request)

**Validation Questions:**

1. Are 100% of requests traceable through full flow?
2. Do traces explain WHY (reasoning), not just WHAT (events)?
3. Can traces be used to diagnose production issues?

**Exit Criteria:**

- [ ] ADR-1050 written and accepted
- [ ] All evidence artifacts created
- [ ] All validation questions answered (YES)

---

### ADR-1053: ACOS Deployment Model

**Status:** NOT YET WRITTEN (P2-B not started)

**When Written, Trace to:**

**Success Criteria:**
- Production Deployment (SUCCESS-CRITERIA-PER-LEVEL.md, P2-B Level 1)

**Quality Attributes:**
- QA-AVAIL-001: System Uptime (99% per month)
- QA-PERFORM-001: Context Assembly Latency (<500ms p95)

**Evidence Required:**
- EVD-030-L3: Deployment Logs (successful deployment)
- EVD-031-L3: Health Check Response (HTTP 200)
- EVD-032-L3: Studio Integration Test (production environment)

**Validation Questions:**

1. Is Ontory deployed to production environment?
2. Is production URL operational?
3. Is Studio successfully consuming production Ontory endpoint?

**Exit Criteria:**

- [ ] ADR-1053 written and accepted
- [ ] All evidence artifacts created
- [ ] All validation questions answered (YES)

---

## P1 ADRs (During Implementation)

### ADR-1005: Provider Failover Strategy

**Status:** NOT YET WRITTEN (may be written during P2-B)

**When Written, Trace to:**

**Success Criteria:**
- Availability (SUCCESS-CRITERIA-PER-LEVEL.md, Cross-Cutting)

**Quality Attributes:**
- QA-AVAIL-001: System Uptime (99% per month)
- QA-AVAIL-002: Incident Detection (<5 minutes)

**Evidence Required:**
- EVD-040-L3: Failover Test
- EVD-041-L4: Chaos Test (random provider failures)

**Exit Criteria:**

- [ ] ADR-1005 written and accepted (if needed during P2-B)
- [ ] All evidence artifacts created (if ADR written)

---

### ADR-1007: Provider Capability Parity

**Status:** NOT YET WRITTEN (may be written during P2-B)

**When Written, Trace to:**

**Success Criteria:**
- Capability Parity (SUCCESS-CRITERIA-PER-LEVEL.md, P2-B Level 1)

**Quality Attributes:**
- QA-EXTEND-001: New Provider Integration (<2 days)

**Evidence Required:**
- EVD-050-L3: Capability Parity Matrix
- EVD-051-L2: Provider Capability Documentation

**Exit Criteria:**

- [ ] ADR-1007 written and accepted (if needed during P2-B)
- [ ] All evidence artifacts created (if ADR written)

---

### ADR-1008: Provider Observability

**Status:** NOT YET WRITTEN (may be written during P2-B)

**When Written, Trace to:**

**Success Criteria:**
- Observability (SUCCESS-CRITERIA-PER-LEVEL.md, P2-B Level 1)

**Quality Attributes:**
- QA-PERFORM-002: Request Traceability (100%)

**Evidence Required:**
- EVD-060-L3: Provider Trace Examples

**Exit Criteria:**

- [ ] ADR-1008 written and accepted (if needed during P2-B)
- [ ] All evidence artifacts created (if ADR written)

---

### ADR-1055: ACOS Testing Strategy

**Status:** NOT YET WRITTEN (may be written during P2-B)

**When Written, Trace to:**

**Success Criteria:**
- Engineering Quality (SUCCESS-CRITERIA-PER-LEVEL.md, Cross-Cutting)

**Quality Attributes:**
- QA-MAINT-002: Test Coverage (≥80%, critical paths ≥95%)

**Evidence Required:**
- EVD-070-L3: Test Coverage Report
- EVD-071-L3: CI/CD Pipeline Green

**Exit Criteria:**

- [ ] ADR-1055 written and accepted (if needed during P2-B)
- [ ] All evidence artifacts created (if ADR written)

---

### ADR-1056: ACOS CI/CD Pipeline

**Status:** NOT YET WRITTEN (may be written during P2-B)

**When Written, Trace to:**

**Success Criteria:**
- Engineering Quality (SUCCESS-CRITERIA-PER-LEVEL.md, Cross-Cutting)

**Quality Attributes:**
- QA-AVAIL-001: System Uptime (CI/CD reliability)

**Evidence Required:**
- EVD-080-L3: CI/CD Pipeline Configuration
- EVD-081-L3: CI/CD Pipeline Run Logs

**Exit Criteria:**

- [ ] ADR-1056 written and accepted (if needed during P2-B)
- [ ] All evidence artifacts created (if ADR written)

---

## Evidence Artifact Template

**When creating evidence artifacts, use this template:**

```markdown
---
evidence-id: EVD-XXX
quality-level: L3
claim: [Architectural claim being validated]
adr-reference: ADR-XXXX
success-criteria: [Reference to SUCCESS-CRITERIA-PER-LEVEL.md]
quality-attribute: [Reference to QUALITY-ATTRIBUTE-SCENARIOS.md]
test-date: [YYYY-MM-DD]
commit: [Git commit hash]
reviewer: [Reviewer name]
---

# Evidence: [Short Description]

## 1. What was tested?

[Exact feature/capability tested]

## 2. How was it tested?

[Test method, test type, test tool]

## 3. When was it tested?

[Date, time, duration]

## 4. Which commit/version?

[Git commit hash, branch name]

## 5. What was the configuration?

[Environment, config files, providers]

## 6. What was the expected result?

[Expected behavior, success criteria]

## 7. What was the actual result?

[Actual behavior, pass/fail, deviations]

## 8. What is the quality level?

[L1/L2/L3/L4, justification]

## 9. How can it be reproduced?

[Exact reproduction steps, commands]

## Traceability

**ADR:** ADR-XXXX  
**Success Criteria:** [Reference]  
**Quality Attribute:** [Reference]

## Reviewer Sign-Off

**Reviewer:** [Name]  
**Date:** [YYYY-MM-DD]  
**Status:** [Accepted/Rejected/Needs Revision]
```

---

## Traceability Validation Checklist

**Before P2-B completion, verify:**

### Forward Traceability (ADR → Evidence)

- [ ] Every P0 ADR has ≥2 evidence artifacts (L3+)
- [ ] Every P1 ADR (if written) has ≥1 evidence artifact (L3+)
- [ ] Every ADR traces to ≥1 Success Criteria
- [ ] Every ADR traces to ≥1 Quality Attribute

### Backward Traceability (Evidence → ADR)

- [ ] Every evidence artifact traces to ≥1 ADR
- [ ] Every evidence artifact traces to ≥1 Success Criteria
- [ ] Every evidence artifact traces to ≥1 Quality Attribute
- [ ] No orphan evidence artifacts (evidence without ADR reference)

### Completeness

- [ ] All Success Criteria have ≥1 evidence artifact
- [ ] All Quality Attributes (relevant to P2-B) have ≥1 evidence artifact
- [ ] Traceability matrix complete (no gaps)

---

## Governance Rules

### Rule 1: No ADR Without Evidence

> If an ADR is written, it MUST have evidence validating its claims.

**Process:**

```
ADR Written
    ↓
Implementation
    ↓
Evidence Captured → Trace to ADR
    ↓
ADR Status: Validated
```

---

### Rule 2: No Evidence Without ADR Reference

> If evidence is created, it MUST reference the ADR it validates.

**Process:**

```
Evidence Captured
    ↓
ADR Reference Added (front matter)
    ↓
Evidence Accepted
```

---

### Rule 3: Traceability Review REQUIRED at P2-B Completion

> Before declaring P2-B complete, traceability matrix MUST be validated.

**Process:**

```
P2-B Implementation Complete
    ↓
Traceability Validation (all checklists)
    ↓
Gaps Identified? → YES → Address Gaps
    ↓ NO
Traceability Validated ✅
```

---

## Anti-Patterns

### ❌ Anti-Pattern 1: Evidence Without ADR

**Example:**

> "EVD-001: Provider swap test passed."
> 
> ADR Reference: (none)

**Why Wrong:**

- Evidence purpose unclear
- Cannot validate architectural claim

**Correct Approach:**

```
ADR Reference: ADR-1001 (Provider Abstraction Strategy)
```

---

### ❌ Anti-Pattern 2: ADR Without Evidence

**Example:**

> "ADR-1001: Provider Abstraction Strategy"
> 
> Evidence: (none)

**Why Wrong:**

- ADR is a claim without proof
- Cannot validate architectural decision

**Correct Approach:**

- Create EVD-001-L3-provider-swap-test.md
- Create EVD-002-L3-provider-abstraction-test-suite.md

---

### ❌ Anti-Pattern 3: Incomplete Traceability

**Example:**

> "EVD-001 traces to ADR-1001."
> 
> Success Criteria: (none)  
> Quality Attribute: (none)

**Why Wrong:**

- Cannot validate against success criteria
- Cannot validate quality attributes

**Correct Approach:**

- Add Success Criteria: Provider Independence (P2-B Level 1)
- Add Quality Attribute: QA-MAINT-001 (Provider Addition)

---

## Summary

**ADR Traceability Matrix Purpose:**

1. Ensure every ADR has evidence
2. Ensure every evidence artifact traces to ADR
3. Ensure traceability to Success Criteria and Quality Attributes
4. Enable Architecture Assessment to validate Stage 1.0

**Governance:**

- No ADR without evidence
- No evidence without ADR reference
- Traceability review required at P2-B completion

**Outcome:**

> If P2-B maintains complete traceability, Architecture Assessment can validate which architectural claims are proven and which require further validation.

---

**Document Version:** 1.0 (FINAL)  
**Date:** 2026-07-11  
**Status:** Living Document (Updated During P2-B)  
**Authority:** Chief Architect  
**Cross-Reference:** 00-EVIDENCE-QUALITY-FRAMEWORK.md, P2-B-DEFINITION-OF-DONE.md, SUCCESS-CRITERIA-PER-LEVEL.md, QUALITY-ATTRIBUTE-SCENARIOS.md
